Clinical Trial Update: Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial evaluating ibrutinib in c-MYC and HER2 amplified oesophagogastric carcinoma (gastroesophageal cancer).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Cancer
• Gastroesophageal Cancer

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Gastrooesophageal Cancer | Phase 2 | Status: UNKNOWN